Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges

Natthawadee Laokulrath; Mihir Gudi; Syed Ahmed Salahuddin; Angela Phek Yoon Chong; Cristine Ding; Jabed Iqbal; Wei Qiang Leow; Benjamin Yongcheng Tan; Gary Tse; Emad Rakha; Puay Hoon Tan

doi:10.1111/his.15213

Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges

Natthawadee Laokulrath, Mihir Gudi, Syed Ahmed Salahuddin, Angela Phek Yoon Chong, Cristine Ding, Jabed Iqbal, Wei Qiang Leow, Benjamin Yongcheng Tan, Gary Tse, Emad Rakha, Puay Hoon Tan

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens. Recently, the emerging eligibility of patients with HER2-low breast cancers for a novel HER2-targeted antibody-drug conjugate (T-DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0-1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.

Original language	English
Pages (from-to)	371-382
Number of pages	12
Journal	Histopathology
Volume	85
Issue number	3
DOIs	https://doi.org/10.1111/his.15213
Publication status	Published - Sept 2024
Externally published	Yes

Keywords

breast cancer
HER2
HER2 scoring
HER2-low

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/his.15213

Cite this

@article{3c2f4d307fea46208130194e34dce3f6,

title = "Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges",

abstract = "Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens. Recently, the emerging eligibility of patients with HER2-low breast cancers for a novel HER2-targeted antibody-drug conjugate (T-DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0-1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.",

keywords = "breast cancer, HER2, HER2 scoring, HER2-low",

author = "Natthawadee Laokulrath and Mihir Gudi and Salahuddin, {Syed Ahmed} and Chong, {Angela Phek Yoon} and Cristine Ding and Jabed Iqbal and Leow, {Wei Qiang} and Tan, {Benjamin Yongcheng} and Gary Tse and Emad Rakha and Tan, {Puay Hoon}",

year = "2024",

month = sep,

doi = "10.1111/his.15213",

language = "English",

volume = "85",

pages = "371--382",

journal = "Histopathology",

issn = "0309-0167",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Human epidermal growth factor receptor 2 (HER2) status in breast cancer

T2 - practice points and challenges

AU - Laokulrath, Natthawadee

AU - Gudi, Mihir

AU - Salahuddin, Syed Ahmed

AU - Chong, Angela Phek Yoon

AU - Ding, Cristine

AU - Iqbal, Jabed

AU - Leow, Wei Qiang

AU - Tan, Benjamin Yongcheng

AU - Tse, Gary

AU - Rakha, Emad

AU - Tan, Puay Hoon

PY - 2024/9

Y1 - 2024/9

N2 - Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens. Recently, the emerging eligibility of patients with HER2-low breast cancers for a novel HER2-targeted antibody-drug conjugate (T-DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0-1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.

AB - Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens. Recently, the emerging eligibility of patients with HER2-low breast cancers for a novel HER2-targeted antibody-drug conjugate (T-DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0-1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.

KW - breast cancer

KW - HER2

KW - HER2 scoring

KW - HER2-low

UR - http://www.scopus.com/inward/record.url?scp=85195451811&partnerID=8YFLogxK

UR - https://go.openathens.net/redirector/westernsydney.edu.au?url=https://doi.org/10.1111/his.15213

U2 - 10.1111/his.15213

DO - 10.1111/his.15213

M3 - Article

C2 - 38845396

AN - SCOPUS:85195451811

SN - 0309-0167

VL - 85

SP - 371

EP - 382

JO - Histopathology

JF - Histopathology

IS - 3

ER -

Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this